New reporting from The New York Times raises important questions about how clinical trials are conducted and overseen—and what that may mean for patient safety and informed consent.

Clinical trials are essential, but they do not always capture the full picture of how medications affect individuals in real-world settings. Early warning signs—especially medication-induced effects like akathisia—can be missed or misunderstood. In some previous clinical drug trials, akathisia was miscoded, downplaying the likely cause of suicidality and suicide as adverse drug effects and events.

At MISSD, we emphasize the importance of:

• Careful monitoring after starting, stopping, or changing medications
• Listening closely to patient-reported experiences
• Recognizing early signs of medication-induced distress

These steps can help prevent serious and sometimes life-threatening outcomes.

👉 Note: This article is behind a paywall. https://www.nytimes.com/2026/04/13/well/fda-clinical-trials.html,

A recent article spotlights important questions about antidepressant use in children. Analyses suggest limited benefit in certain cases, while prescribing rates continue to rise. Other findings highlight the need for careful monitoring and greater awareness of potential risks—especially with longer-term use.

These concerns underscore a broader issue: how we understand and respond to childhood distress. Children and families deserve a full range of support, including evidence-based therapies and non-drug approaches.

The goal is not to dismiss treatment, but to ensure it is measured, informed, and centered on the child.Read the full article at https://www.madinamerica.com/2026/04/questioning-the-prescription-antidepressants-and-the-medicalization-of-childhood/.

We appreciate this article’s intention to share information about antidepressants for older adults and its attention to common side effects such as weight changes, cardiovascular effects, and drug interactions.

However, one serious risk is not addressed: medication-induced akathisia.

Older adults are at higher risk of akathisia and adverse drug effects, making awareness and early recognition especially important. Education about akathisia is essential for safer prescribing and truly informed care. Read more at https://www.aol.com/news/choose-best-antidepressant-older-adults-165900746.html.

We’re encouraged to see increased awareness of prescribed harm and the growing number of lived experiences being shared: https://prescribed-harm.com/

At MISSD, we have amplified similar stories to improve patient safety and deepen understanding of akathisia and related medication-induced harms.

While MISSD focuses on akathisia, it is not the only form of medication-induced harm that can precipitate suicide. Other serious effects may include post-SSRI sexual dysfunction (PSSD), emotional blunting, and loss of emotional responsiveness.

Adverse drug events are among the leading causes of death, yet remain widely under-recognized. Sharing lived experience helps improve recognition, informed consent, and ultimately—saves lives.

A season centered on awareness and reflection reminds us that recognizing suffering early can make all the difference.

At MISSD, we regularly feature and amplify first-person accounts that illuminate the very real risks of adverse med effects—particularly the torment of akathisia and protracted withdrawal syndromes. Lori Daniels’ latest essay, ‘I Can Barely Breathe: The Journey Continues,’ is one such account. She was entangled in a system amid a circle of misdiagnosis—beginning with a coerced introduction to neuroleptics as a teenager and a cocktail of drugs that treated side effects with more side effects.

Her description of ongoing symptoms (akathisia, dystonia, myoclonic jerks, insomnia, and the sense that ‘breathing’ itself must be redefined) aligns with what countless others have reported when attempting to withdraw from long-term psychiatric drug use. Too often, these symptoms are dismissed or misattributed back to the original ‘disorder.’ We are grateful for voices like Lori’s and her full story that can help reduce these avoidable harms.

MISSD recently presented at the Washington, DC Psychotherapy Networker Symposium, delivering a Lunch & Learn session focused on the recognition and risks of akathisia.

Akathisia is a serious and often unrecognized medication-induced disorder associated with profound distress and potentially life-threatening outcomes. Early identification remains critical to improving patient safety. During the session, MISSD provided education on:

• Recognizing akathisia in clinical and real-world settings
• The importance of assessing symptoms in relation to medication changes
• Strategies to support earlier identification and reduce misdiagnosis

In addition to the presentation, MISSD maintained an exhibit presence throughout the symposium, engaging with thousands of attending clinicians and distributing educational materials to expand awareness of medication-induced harm.

MISSD also highlighted its free accredited online courses, developed to support clinicians, patients, and caregivers in recognizing akathisia and improving safety outcomes.

Register for the courses at MISSD.LearnUpon.com

MISSD continues its national and international efforts to advance recognition, education, and prevention of medication-induced harm that can cause self-harm, violence, and suicide.

MISSD founder, Wendy Dolin, and therapist Dr. Linda Stern prepare to greet symposium attendees and share MISSD’s educational resources.

It’s National Adverse Drug Event Awareness Day and an appropriate time to highlight key protocols to improve patient safety. See our latest Akathisia Stories podcast, new Understanding Akathisia video and take our free courses. Read our press release and follow the links here: https://www.einpresswire.com/article/901408014/medication-reactions-often-missed-and-misdiagnosed-experts-warn

The U.S. FDA has issued a warning letter to Novo Nordisk citing incomplete reporting of postmarketing adverse events associated with semaglutide (Ozempic, Wegovy), including serious outcomes such as deaths and a suicide.

While causation has not been established, incomplete reporting can delay recognition of potential medication-induced harms. MISSD previously highlighted emerging reports of psychiatric effects associated with GLP-1 medications, including akathisia, anxiety, and medication-induced suicidality:
https://missd.co/a-popular-weight-loss-drug-is-being-associated-with-medication-induced-suicidality

What to monitor:

• Sudden inner restlessness or agitation
• New or worsening anxiety or depression
• Suicidal thoughts or behavioral changes

Recommended actions:

• Contact your prescriber if symptoms arise
• Report adverse events to FDA MedWatch
• Use a trusted support person when starting or changing medications

MISSD supports informed decision-making, transparency, and education to improve patient safety. Take our free courses and see our educational resources available via the “Resources” link at the top of our website.

Research from Queen’s University Belfast, reported by The Mirror, analyzed more than 14,000 dementia cases in Northern Ireland and found antidepressant use associated with a slight increase in mortality risk. Anti-anxiety medications showed a stronger association.

The medications mentioned include commonly prescribed SSRIs such as sertraline, citalopram, and fluoxetine.

While these medications help many patients, the findings underscore the importance of careful prescribing and regular medication reviews, particularly among vulnerable populations.

Adverse reactions such as akathisia—a medication-induced disorder characterized by profound subjective inner restlessness and psychological distress—can be overlooked and misattributed to underlying illness.

MISSD continues to advocate for greater awareness of medication-induced akathisia and informed prescribing practices. Learn more through MISSD’s free online courses. Enroll at MISSD.LearnUpon.

Read the full article:
https://www.mirror.co.uk/news/health/new-warning-taking-drugs-like-36834321